PMP22 and Charcot-Marie-Tooth disease type 1A: Both shRNAs were found to be effective in reducing human PMP22 in HEK293 cells (Supplementary Fig. S6a), showing that decreasing PMP22 expression in mSC may represent a relevant therapeutic approach for CMT1A disease.